We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00172380
First Posted: September 15, 2005
Last Update Posted: December 20, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Taiwan University Hospital
September 12, 2005
September 15, 2005
December 20, 2012
February 2005
January 2010   (Final data collection date for primary outcome measure)
overall response rate [ Time Frame: every cycle during 2nd-6th cycles ]
Not Provided
Complete list of historical versions of study NCT00172380 on ClinicalTrials.gov Archive Site
  • resectability [ Time Frame: resectability after treatment ]
  • progression free survival [ Time Frame: progression free survival after 1 year ]
  • overall survival [ Time Frame: overall survival at 1 year ]
Not Provided
Not Provided
Not Provided
 
Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
Phase II Study Evaluating Docetaxel and CDDP as Neoadjuvant Chemotherapy Prior to Surgery, Followed by Adjuvant Docetaxel Plus CDDP in Chemonaive Patients With NSCLC Stage III
To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
NSCLC
Drug: Docetaxel Plus CDDP
docetaxel 36mg/m2 and cisplatin 75mg/m2
Experimental: docetaxel and cisplatin
docetaxel 36mg/m2 and cisplatin 75mg/m2
Intervention: Drug: Docetaxel Plus CDDP
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
41
March 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T1-2 N2 or or unresectable stage IIIb 2.KPS>70% 3.Hb>10g/dl,ANC>2.0x109/L,Plt.>100x109/L4.T-bil.<1xULN,creatinine<1xULN,creatinine clearance >60 ml/min,GPT/GOT<2.5xULN,ALP<5xULN

Exclusion Criteria:

  • 1.Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT00172380
930911
No
Not Provided
Not Provided
National Taiwan University Hospital
National Taiwan University Hospital
Not Provided
Principal Investigator: Chong-Jen Yu, M.D,Ph.D. Department of Internal Medicine, National Taiwan University hospital
National Taiwan University Hospital
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP